Examining HSD3B1 as a possible biomarker to detect prostate cancer patients who are likely to progress on ADT

Whitney F Handy; Keith T Schmidt; Douglas K Price; William D Figg

doi:10.1080/15384047.2020.1796195

Examining HSD3B1 as a possible biomarker to detect prostate cancer patients who are likely to progress on ADT

Cancer Biol Ther. 2020 Sep 1;21(9):782-784. doi: 10.1080/15384047.2020.1796195. Epub 2020 Aug 13.

Authors

Whitney F Handy¹, Keith T Schmidt², Douglas K Price³, William D Figg^{2

3}

Affiliations

¹ Bernard J. Dunn School of Pharmacy, Shenandoah University , Fairfax, VA, USA.
² Clinical Pharmacology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health , Bethesda, MD, USA.
³ Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health , Bethesda, MD, USA.

Abstract

The Chemohormonal Therapy vs Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer (CHAARTED) was a randomized phase III trial that evaluated the outcomes of men with metastatic prostate cancer who received castration with or without docetaxel. Patients from this trial were genotyped in a recent study to detect HSD3B1 variance and to determine 2-y freedom from castration-resistant prostate cancer as well as overall survival. The results of this study identified HSD3B1 as a possible biomarker that can be used to predict response to therapy in patients with metastatic disease.

Keywords: ADT; CRPC; HSD3B1; docetaxel; germline mutations.

Publication types

Research Support, N.I.H., Extramural
Comment

MeSH terms

Androgen Antagonists*
Biomarkers
Castration
Genotype
Humans
Male
Multienzyme Complexes / genetics
Prostatic Neoplasms* / drug therapy
Prostatic Neoplasms* / genetics
Treatment Outcome

Substances

Androgen Antagonists
Biomarkers
Multienzyme Complexes

Grants and funding

This study was funded by the National Institutes of Health.